Determine the necessary mass, volume, or concentration for preparing a solution.
BMS-191095 - 10mM in DMSO , CAS No.166095-21-2
AVAILABLE TO ORDER
GRADE & PURITY 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium ( mitoKATP ) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels .
In Vitro
BMS-191095 (50 μmol/L) induces mitochondrial depolarization of vascular smooth muscle (VSM) cells from SD rats. BMS-191095 (10-100 μmol/L) dose-dependently induces vasodilation in endothelium denuded cerebral arteries. BMS-191095 (50 μmol/L) increases the frequency of calcium sparks in VSM cells. BMS-191095 (0-1500 μM) inhibits human platelet aggregation induced by collagen and thrombin with IC 50 values of 63.9 and 104.8 μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BMS-191095 (2.5 or 25 μg; intraventricular infusion, 30 min/60 min/24 hours before the induction of ischemia, once) reduces neuronal damage in rats with transient focal cerebral ischemia. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats with the induction of ischemia induced by middle cerebral artery occlusion (MCAO)Dosage: 2.5 or 25 μg Administration: Intraventricular infusion; 30 min/60 min/24 hours before the induction of ischemia, once Result: Reduced total infarct volume in rats with of pretreat dose of 25 mg and 24 h before MCA. Induced a rapid mitochondrial depolarization.
Specifications
Specifications & Purity
10mM in DMSO
Biochemical and Physiological Mechanisms
BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium ( mitoKATP ) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels.
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
ACTIVATOR
Names and Identifiers
| Isomeric SMILES | CC1([C@@H]([C@H](C2=C(O1)C=CC(=C2)C#N)N(CC3=NC=CN3)C4=CC=C(C=C4)Cl)O)C |
|---|---|
| Alternate CAS | 166095-21-2 |
| PubChem CID | 9822753 |
| MeSH Entry Terms | BMS 191095;BMS-191095;BMS191095 |
| Molecular Weight | 408.88 |
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.